Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.2K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.2K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.5K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.5K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of abstinence from chronic alcohol consumption on the mouse striatal proteome: sex and subregion-specific differences.

Frontiers in pharmacology·2024
Same author

Alcohol reinstatement after prolonged abstinence from alcohol drinking by female adolescent rats: Roles of cyclooxygenase-2 and the prostaglandin E<sub>2</sub> receptor 1.

Drug and alcohol dependence·2022
Same author

The effects of alcohol drinking on subsequent methamphetamine self-administration and relapse in adolescent female rats.

Behavioural brain research·2022
Same author

Combined and sequential effects of alcohol and methamphetamine in animal models.

Neuroscience and biobehavioral reviews·2021
Same author

Roflumilast treatment during forced abstinence reduces relapse to methamphetamine seeking and taking.

Addiction biology·2021
Same author

Toxic Effects of Methamphetamine on Perivascular Health: Co-morbid Effects of Stress and Alcohol Use Disorders.

Current neuropharmacology·2021
Same journal

Environmental Concentrations of PFOS Accumulate in the <i>Euglena</i> Eyespot and Impair Chloroplast ATP Synthase Activity: A Dual Impairment of Phototaxis and Photosynthetic Light Reactions.

Toxics·2026
Same journal

Heavy Metal(loid) Pollution Characteristics and Risk Assessment in the Water-Soil-Vegetable System of a Watershed in Southwest China.

Toxics·2026
Same journal

Sludge Retention Time Governs Ectoine Synthesis and Pollutant Removal in Halophilic Activated Sludge Treating High-Salinity Wastewater.

Toxics·2026
Same journal

Interpretable Machine Learning and Spatiotemporal Modeling of Meteorological and Environmental Drivers for Tuberculosis Incidence in China.

Toxics·2026
Same journal

A 3D Graphene Oxide Model Reveals Fine Particulate Matter Induced Cell Cycle Dysregulation in Neural Stem Cells.

Toxics·2026
Same journal

Storage-Dependent Changes in Microplastic-Associated Recoverable Residues in Yogurt Containing <i>Bifidobacterium longum</i> subsp. <i>infantis</i>.

Toxics·2026
See all related articles

Related Experiment Video

Updated: Feb 20, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.5K

L-Dopa and Brain Serotonin System Dysfunction.

Branden J Stansley1, Bryan K Yamamoto2

  • 1Department of Neurosciences, University of Toledo College of Medicine, 3000 Arlington Ave, Toledo, OH 43561, USA. branden.stansley@utoledo.edu.

Toxics
|October 24, 2017
PubMed
Summary
This summary is machine-generated.

Levodopa (L-dopa) treatment for Parkinson's disease may harm serotonin neurons. This can lead to serotonin deficits, potentially causing side effects like mood and cognitive issues.

Keywords:
6-hydroxydopamineL-dopaParkinson’s diseasedopaminenon-motor symptomsserotonin neurons

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.9K

Related Experiment Videos

Last Updated: Feb 20, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.9K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurodegenerative Diseases

Background:

  • Parkinson's disease involves dopamine neuron loss, treated with Levodopa (L-dopa).
  • L-dopa is a dopamine precursor that crosses the blood-brain barrier.
  • Serotonin neurons play a role in dopamine production from L-dopa.

Purpose of the Study:

  • To review evidence on L-dopa's impact on serotonin neurons.
  • To explore how dopamine from L-dopa affects serotonin systems.
  • To link L-dopa-induced serotonin deficits to Parkinson's side effects.

Main Methods:

  • Review of existing scientific literature and findings.
  • Analysis of studies investigating dopamine-serotonin interactions.
  • Examination of evidence for oxidative stress and neuronal damage.

Main Results:

  • Dopamine produced from L-dopa is partly mediated by serotonin neurons.
  • Increased dopamine levels can cause oxidative stress and damage serotonin neurons.
  • Chronic L-dopa treatment leads to reduced serotonin neurotransmission and concentrations.

Conclusions:

  • L-dopa treatment can negatively impact serotonin systems.
  • These serotonin deficits may contribute to side effects in Parkinson's patients.
  • Further research is needed to understand and mitigate these effects.